ACB Stock Overview
Engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Aurora Cannabis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$4.50 |
| 52 Week High | CA$9.35 |
| 52 Week Low | CA$2.84 |
| Beta | 2.64 |
| 1 Month Change | 2.04% |
| 3 Month Change | -18.18% |
| 1 Year Change | -5.34% |
| 3 Year Change | -91.62% |
| 5 Year Change | -97.98% |
| Change since IPO | -88.02% |
Recent News & Updates
Recent updates
Aurora Cannabis: Revving Up To Profitability
Aug 08Aurora launches new cannabis products for adult and medical-use
Oct 17Aurora Cannabis further strengthens its balance sheet by repurchasing ~US$23M of convertible notes
Oct 07Aurora Cannabis Q4 2022 Earnings Preview
Sep 19Aurora Cannabis: Don't Let Your Money Go Up In Smoke
Aug 25Why Did Aurora Cannabis Stock Crash In May; Can It Recover?
Jun 13Recent Developments Do Not Change Our Stance On Aurora Cannabis
May 13Aurora Cannabis: A Train Wreck Desperate For Help
May 05Aurora Cannabis: The Fallen Pot Giant That Still Can't Find Its Way
Feb 17Aurora Cannabis Vs. HEXO: Which Is The Better Cannabis Stock?
Dec 17Tilray Vs. Aurora Cannabis: How To Compare These Cannabis Stocks
Oct 11Aurora Cannabis: Investors Should Have No Confidence In This Company
Sep 28Is Aurora Cannabis Stock A Buy Or Sell Before Upcoming Earnings? Buy The U.S. Opportunity
Sep 16Aurora Cannabis Is A Pass For Now, Although We Are Bullish On The Industry
Jun 05Aurora Cannabis: Extreme Downside Case Averted
Feb 02Shareholder Returns
| ACB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.7% | -1.9% | -2.8% |
| 1Y | -5.3% | 2.7% | 24.1% |
Return vs Industry: ACB underperformed the US Pharmaceuticals industry which returned 2.7% over the past year.
Return vs Market: ACB underperformed the US Market which returned 24.1% over the past year.
Price Volatility
| ACB volatility | |
|---|---|
| ACB Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACB's weekly volatility has decreased from 14% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 1,073 | Miguel Martin | www.auroramj.com |
Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers medical and consumer cannabis products; supplies propagated vegetables and ornamental plants; and distributes and sells hemp-derived cannabidiol (CBD) products.
Aurora Cannabis Inc. Fundamentals Summary
| ACB fundamental statistics | |
|---|---|
| Market cap | US$232.68m |
| Earnings (TTM) | -US$20.67m |
| Revenue (TTM) | US$206.23m |
1.2x
P/S Ratio-12.0x
P/E RatioIs ACB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACB income statement (TTM) | |
|---|---|
| Revenue | CA$296.99m |
| Cost of Revenue | CA$139.24m |
| Gross Profit | CA$157.75m |
| Other Expenses | CA$187.52m |
| Earnings | -CA$29.76m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 53.12% |
| Net Profit Margin | -10.02% |
| Debt/Equity Ratio | 9.9% |
How did ACB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 08:22 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aurora Cannabis Inc. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Frederico Yokota Choucair Gomes | ATB Capital Markets |
| Tamy Chen | BMO Capital Markets Equity Research |
| Heather Balsky | BofA Global Research |